CRBI/CIRC Seminar
CRBI Seminar - Dr. Igor Jurisica, Medical Biophysics, University of Toronto Ai is not Enough: Explainable Biology for Improved Therapies
10 events found.
Dr. Igor Jurisica
AI is Not Enough: Explainable Biology for Improved Therapies: Integrative computational biology and AI help improving treatment of complex diseases by building explainable models. From systematic data analysis to improved biomarkers, drug mechanism of action, and patient selection, such analyses influence multiple steps of drug discovery pipeline. Data mining, machine learning, graph theory and advanced …
CRBI/CIRC Seminar
CRBI Seminar - Dr. Frank Delaglio, Professor, University of Leicester, UK Exploiting NMR for Biomanufacturing needs
Dr. Frank Delaglio
Abstract Protein therapeutics are a highly successful class of drugs that are used to treat a number of serious and life-threatening conditions such as cancer, autoimmune disorders, and infectious diseases including COVID-19. These therapeutics have numerous critical quality attributes (CQA) that must be evaluated to ensure safety and efficacy, including that they must adopt and …
CRBI/CREATE Joint Conference – 2022
Schulich School of BusinessCRBI/CIRC Seminar
CRBI Seminar - Dr. Jennilee Gavina, Research Scientist, Gilead How can you as an analytical chemist contribute towards developing life saving medicines within the pharmaceutical industry
In person seminar by Dr. Jennilee Gavina
Petrie Building - Room 317How can you as an analytical chemist contribute towards developing lifesaving medicines within the pharmaceutical industry? Let's explore this rewarding career path through learning the whats, whys, and hows. First, we’ll cover some basics about Good Manufacturing Practice (GMP) and regulatory requirements so we can understand what characteristics of a compound need to be controlled …
CRBI/CIRC Seminar
CRBI Seminar - Dr. Terry Sachlos, Associate Professor - Teaching Stream, York University New paradigm of leukemic stem cells and how they can be targeted using differentiation therapy as novel therapeutic strategy
In person seminar with Dr. Sachlos
Life Sciences Buliding (LSB) 107Acute myeloid leukemia is a fatal blood cancer. The malignant AML blast cells rapidly overwhelm the bone marrow, disrupting resident hematopoietic stem cells (HSC) and normal blood production and eventually causing death. Treatment involves the administration of DNA-binding chemotherapeutic agents that indiscriminately kill both HSC and progenitors, leading to myelosuppression and ultimately drug dose attenuation. Ideally, drugs should specifically target …